Genital Warts Clinical Trial
Official title:
A Phase 3 Open-Label Immunogenicity and Safety Study of 2-Dose Regimens of V503, a 9-Valent Human Papillomavirus (HPV) Vaccine in Chinese Males 9 Through 14 Years Old and 3-Dose Regimen of V503 in Chinese Males 9 Through 19 Years Old
Verified date | January 2023 |
Source | Merck Sharp & Dohme LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASILâ„¢9, V503) in Chinese males 9 through 19 years of age, and 2 doses of the 9vHPV vaccine in Chinese males 9 through 14 years of age, compared to the 3 dose regimen in Chinese males 20 through 26 years of age (from Merck Protocol V503-052). The primary hypothesis is that each of the 3-dose regimen in Chinese males aged 9 through 19 years and 2-dose regimens in Chinese males aged 9 through 14 years induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) at one month post last dose compared to the 3-dose regimen in Chinese adult males aged 20 through 26 years. A noninferiority margin of 0.67 in the GMT ratio (9 through 19 years of age or 9 through 14 years of age vs 20 through 26 years of age) is used for each HPV type.
Status | Active, not recruiting |
Enrollment | 1590 |
Est. completion date | February 19, 2029 |
Est. primary completion date | February 19, 2029 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 9 Years to 19 Years |
Eligibility | Inclusion Criteria: - Is a healthy Chinese male. - Has not had sexual debut at the time of enrollment, and does not plan on becoming sexually active during the vaccination period (Day 1 through one month post last dose). Exclusion Criteria: - Has a history of known prior vaccination with an HPV vaccine. - Has a history of HPV-related external genital lesions, HPV-related intra-anal lesions, or HPV-related head and neck cancer. - Has a history of severe allergic reaction that required medical intervention. - Has received immune globulin or blood-derived products in the past 6 months or plans to receive any before one month post last dose. - Has a history of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, human immunodeficiency virus (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition. - Has received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids and certain regimens of systemic corticosteroids. - Has a known thrombocytopenia or coagulation disorder that would contraindicate IM injections. |
Country | Name | City | State |
---|---|---|---|
China | Yuechi Disease Prevention and Control Center ( Site 0002) | Guang'an | Sichuan |
China | Center for Disease Control and Prevention of Rong An ( Site 0006) | Liuzhou | Guangxi |
China | Liucheng County Centers for Disease Control and Prevention ( Site 0005) | Liuzhou | Guangxi |
China | Loudi Public Health Hospital (Loudi Occupational Disease Prevention And Treatment Hospital) ( Site 0 | Louxing District | Hunan |
China | Santai County Center for Disease Control and Prevention ( Site 0001) | Mianyang | Sichuan |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme LLC |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Competitive Luminex immunoassay (cLIA) GMTs to 9 vaccine types of 9vHPV vaccine at one month post last dose | cLIA GMT to each of 9 vaccine types of 9vHPV vaccine at one month post last dose. The GMT for each HPV type will be reported in mMU/mL. | Up to Month 13 | |
Primary | cLIA GMTs to 9 vaccine types of 9vHPV vaccine up to 60 months post last dose | cLIA GMT to each of 9 vaccine types of 9vHPV vaccine at up to 60 months post last dose. The GMT for each HPV type will be reported in mMU/mL. | Up to 72 months | |
Primary | cLIA seropositivity percentages to 9 vaccine types of 9vHPV vaccine | cLIA seropositivity to each of 9 vaccine types of 9vHPV vaccine. The percentage of participants who are seropositive for each HPV type will be summarized. | Up to 72 months | |
Secondary | cLIA seroconversion percentages to 9 vaccine types of 9vHPV vaccine | cLIA seroconversion to each of 9 vaccine types of 9vHPV vaccine. The percentage of participants who are seropositive for each HPV type will be summarized. | Up to Month 13 | |
Secondary | Immunoglobulin G Luminex immunoassay (IgG LIA) GMTs to 9 vaccine types of 9vHPV vaccine at one month post last dose | IgG LIA GMT to each of 9 vaccine types of 9vHPV vaccine at one month post last dose. The GMT for each HPV type will be reported in mMU/mL. | Up to Month 13 | |
Secondary | IgG LIA seroconversion percentages to 9 vaccine types of 9vHPV vaccine | IgG LIA seroconversion to each of 9 vaccine types of 9vHPV vaccine. The percentage of participants who are seropositive for each HPV type will be summarized. | Up to Month 13 | |
Secondary | Percentage of participants experiencing solicited injection-site adverse events (AEs), | An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Solicited injection-site AEs such as erythema, swelling, pain, and induration at the injection site will be recorded. | Day 1 through Day 8 following any study vaccination | |
Secondary | Percentage of participants experiencing solicited systemic AEs | An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study vaccine. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study vaccine or a protocol-specified procedure, whether or not considered related to the study vaccine or protocol-specified procedure. Systemic AEs are those not categorized as injection-site AEs. | Day 1 through Day 8 following any study vaccination | |
Secondary | Percentage of participants experiencing serious AEs (SAEs) | A SAE is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, or is another important medical event. | Up to 72 months | |
Secondary | IgG LIA GMTs to 9 vaccine types of 9vHPV vaccine up to 60 months post last dose | IgG LIA GMT to each of 9 vaccine types of 9vHPV vaccine up to 60 months post last dose. The GMT for each HPV type will be reported in mMU/mL. | Up to 72 months | |
Secondary | IgG LIA seropositivity percentages to 9 vaccine types of 9vHPV vaccine | IgG LIA seropositivity to each of 9 vaccine types of 9vHPV vaccine. The percentage of participants who are seropositive for each HPV type will be summarized. | Up to 72 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Completed |
NCT03158220 -
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
|
Phase 3 | |
Completed |
NCT01651949 -
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
|
Phase 3 | |
Completed |
NCT00551187 -
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00520598 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
|
Phase 2 | |
Terminated |
NCT01468636 -
A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
|
Phase 4 | |
Recruiting |
NCT03296397 -
Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response
|
Phase 3 | |
Completed |
NCT00674739 -
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
|
Phase 3 | |
Recruiting |
NCT03948321 -
Conventional Photodynamic Therapy vs. Painless Photodynamic Therapy for Small Genital Warts
|
N/A | |
Completed |
NCT00862810 -
Alternate Dosing Schedules Study for HPV Vaccine
|
Phase 4 | |
Completed |
NCT02280642 -
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
|
Phase 4 | |
Completed |
NCT00092482 -
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
|
Phase 3 | |
Completed |
NCT02188004 -
The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases
|
||
Completed |
NCT01553994 -
Effectiveness Study of Gardasil on Condyloma
|
N/A | |
Completed |
NCT00189293 -
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
|
Phase 4 | |
Active, not recruiting |
NCT00092534 -
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
|
Phase 3 | |
Completed |
NCT02462187 -
Topical NVN1000 for the Treatment of External Genital and Perianal Warts
|
Phase 2 | |
Completed |
NCT00501137 -
A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine
|
Phase 3 | |
Active, not recruiting |
NCT02750202 -
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
|
Phase 3 | |
Active, not recruiting |
NCT02653118 -
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
|